Optic Neuritis: Causes, Symptoms, Diagnosis, and Treatment

What is Optic Neuritis?

Optic neuritis is an inflammatory condition affecting the optic nerve, which is the bundle of nerve fibers responsible for transmitting visual information from the eye to the brain. When this nerve becomes inflamed, its ability to conduct visual signals is disrupted, resulting in characteristic symptoms of eye pain and visual disturbance.

Optic neuritis is closely associated with multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system, which accounts for nearly half of all cases of optic nerve inflammation. In many patients, optic neuritis may represent the very first clinical manifestation of MS, making its recognition particularly important. Other causes include autoimmune diseases and systemic infections.

Key Clinical Features at a Glance

• Pain, which typically worsens with eye movement
• Temporary vision loss in the affected eye
• The condition is usually unilateral (affecting one eye), though bilateral involvement is possible

The prognosis is favorable in most cases: the majority of patients recover vision fully or near-fully within a few months. However, approximately one in four patients will experience one or more relapses. Treatment is primarily based on corticosteroids, which leverage their potent anti-inflammatory properties to accelerate recovery.

Anatomy: The Optic Nerve

A brief understanding of the anatomy of the optic nerve helps in appreciating both the symptoms and the mechanisms of optic neuritis.

The optic nerve is the second of the twelve cranial nerve pairs and forms part of the central nervous system (not the peripheral nervous system, as is commonly assumed). It acts as the primary visual relay cable, transmitting electrical impulses generated by the photoreceptors of the retina to the visual cortex of the brain, where they are interpreted as images.

Structurally, it resembles an electrical cable. It is composed of approximately 1..2 million nerve fibers, organized into bundles and protected by a myelin sheath. This sheath is an insulating layer of fatty material that ensures rapid and efficient transmission of electrical signals.

The optic nerve has a total length of approximately 5.1 cm and is anatomically divided into four segments:

1. Intraocular segment: The very short initial portion, running from the retinal ganglion cells to the optic disc (the visible entry point of the nerve into the eye, also called the optic nerve head), and then exiting the globe through a small opening in the sclera (the lamina cribrosa).

2. Intraorbital segment: The longest portion (~2.5 cm), running within the orbital cavity from the posterior pole of the eye to the optic canal in the sphenoid bone. It follows a slightly sinuous course to allow free movement of the eyeball in all directions without placing the nerve under tension.

3. Intracanalicular segment: A short segment passing through the optic canal in the sphenoid bone, where the nerve is in close proximity to the ophthalmic artery.

4. Intracranial segment: Extends from the middle cranial fossa to the optic chiasm, which is the X-shaped structure at the base of the brain. Here, the nasal fibers of each optic nerve cross to the opposite side before continuing to the lateral geniculate nuclei and ultimately to the visual cortex.

Understanding this anatomy explains why inflammation at different points along the nerve produces somewhat different clinical presentations (e.g., retrobulbar neuritis vs. papillitis).

---

Causes

Optic neuritis is most commonly encountered in individuals between the ages of 18 and 50, with a notable predominance in women (approximately 3:1 female-to-male ratio in the demyelinating form associated with MS).

Several distinct forms of the condition are recognized, classified primarily by the location of inflammation along the nerve and its underlying mechanism:

Forms of Optic Neuritis

• Demyelinating optic neuritis: The most common form. It results from immune-mediated damage to the myelin sheath that insulates and protects the optic nerve fibers. This is the form most strongly associated with multiple sclerosis and with other demyelinating conditions such as neuromyelitis optica spectrum disorder (NMOSD).

• Retrobulbar neuritis: Inflammation affecting the posterior (retrobulbar) portion of the optic nerve, located behind the eyeball. In this form, the optic disc appears normal on fundoscopic examination because the inflammation is not at the nerve head. However, the patient still experiences significant visual symptoms, which leads to the classic ophthalmological adage: “The patient sees nothing, and the doctor sees nothing”. Pain on eye movement is also a prominent feature.

• Papillitis (anterior optic neuritis): Inflammation at the optic disc, also called the optic nerve head. This is the portion of the nerve visible through the ophthalmoscope. The disc appears swollen and hyperemic (edematous) on fundoscopy.

Risk Factors and Clinical Correlations

The most important clinical association of optic neuritis is its relationship to multiple sclerosis:

• Optic neuritis is the presenting symptom of MS in approximately 15–20% of patients
• After a first episode of optic neuritis, the 10-year risk of developing MS is approximately 38%, rising to over 50% if MRI brain lesions are already present at the time of the first episode (as shown by the landmark Optic Neuritis Treatment Trial, ONTT)
• Conversely, the risk remains low (~25%) if the initial MRI shows no white matter lesions

Other conditions that can cause or trigger optic neuritis include:

Infectious causes:

• Viral encephalitis (particularly in children)
• Sinusitis (contiguous spread)
• Meningitis
• Tuberculosis
• Syphilis
• HIV infection
• Lyme disease, cat-scratch disease (Bartonella henselae), and other bacterial infections

Neoplastic causes:

• Metastatic spread of cancer along the optic nerve fibers or to surrounding structures

Toxic and drug-induced causes:

• Heavy metals (lead, arsenic)
• Methanol
• Quinine
• Ethambutol (an anti-tuberculosis antibiotic with known optic nerve toxicity)
• Other drugs (some antibiotics, amiodarone, phosphodiesterase inhibitors at high doses)

Neuromyelitis optica spectrum disorder (NMOSD): A distinct autoimmune condition (previously called Devic’s disease), characterized by severe, often bilateral, recurrent optic neuritis and transverse myelitis, associated with anti-AQP4 (aquaporin-4) or anti-MOG (myelin oligodendrocyte glycoprotein) antibodies. NMOSD-associated optic neuritis tends to be more severe and less likely to fully recover than MS-associated optic neuritis.

Rarer causes include:

• Diabetes mellitus (ischemic optic neuropathy more commonly, but inflammatory forms documented)
• Pernicious anemia
• Systemic autoimmune diseases (systemic lupus erythematosus, sarcoidosis, Sjögren’s syndrome)
• Graves’ ophthalmopathy (thyroid eye disease)
• Bee stings or insect bites
• Direct ocular or orbital trauma

In some cases, no underlying cause is identified even after a thorough investigation. These cases are classified as idiopathic optic neuritis.

---

Symptoms

The classic symptomatic triad of optic neuritis consists of:

1. Eye pain: Present in approximately 90% of patients. It is characteristically retro-ocular (behind the eye) and worsens with eye movement, due to traction on the inflamed nerve by the extraocular muscles. Pain may precede visual symptoms or develop simultaneously.

2. Reduced visual acuity: Vision typically deteriorates subacutely over hours to days. The degree of loss varies widely, ranging from mild blurring to near-complete loss of light perception.

3. Color vision disturbance (dyschromatopsia): Particularly affecting the red-green axis. Colors may appear washed out, faded, or less saturated. This is often one of the most sensitive early signs. Many patients don’t notice it until they undergo formal testing or are asked to compare the same image with each eye separately.

Additional Visual Symptoms

• Blurred vision and reduced sharpness
• Central or paracentral scotoma: a dark, grey, or blurred area within the central visual field
• Reduced contrast sensitivity: difficulty distinguishing objects from similar-colored backgrounds
• Phosphenes: flashes of light or visual phenomena perceived in the absence of any external light source, often triggered by eye movement
• Floaters (myodesopsia): moving spots or threads in the visual field
• Sluggish pupillary response to light: An abnormal relative afferent pupillary defect (RAPD), detected by the swinging flashlight test, is one of the most objective and reliable clinical signs of optic nerve dysfunction.
• Optic disc changes: in papillitis (anterior optic neuritis), fundoscopy reveals a swollen, hyperemic optic disc, sometimes with peripapillary exudates or hemorrhages

Uhthoff’s Phenomenon

An important and distinctive feature of optic neuritis (and demyelinating disease in general) is the temporary worsening of symptoms with heat:

• Vigorous physical exercise
• Sun exposure or hot environments
• Fever

This phenomenon, known as Uhthoff’s phenomenon (or Uhthoff’s sign), occurs because elevated body temperature further impairs conduction through nerve fibers that are already demyelinated. It is temporary and causes no permanent damage, and symptoms return to baseline once the body cools down. However, awareness of this phenomenon is important to avoid unnecessary alarm.

---

Complications

Although the majority of patients with optic neuritis achieve good visual recovery, several complications may arise:

Visual Complications

• Recurrent episodes: More than 25% of patients experience a subsequent episode of optic neuritis in the same or the fellow (opposite) eye. Recurrence significantly increases the cumulative risk of permanent vision impairment.

• Optic atrophy: Repeated or severe inflammation can cause permanent structural damage to the optic nerve fibers (axonal loss and subsequent gliosis), leading to irreversible visual deficits, including:

  • Persistent color vision impairment
  • Reduced visual sharpness and contrast sensitivity
  • Impaired depth perception and motion detection
  • In severe cases, persistent significant visual field loss

• Risk of MS diagnosis: As previously discussed, a first episode of optic neuritis carries a substantial long-term risk of developing clinically definite MS, particularly in patients with pre-existing MRI white matter lesions.

Treatment-Related Complications

The use of corticosteroids, though effective, carries a recognized side effect profile.

• Osteoporosis (bone thinning) with long-term or repeated use
• Increased susceptibility to infections
• Weight gain
• Mood changes (including steroid-induced euphoria, anxiety, or depression)
• Gastric discomfort and peptic ulceration are typically managed with a gastroprotective agent, such as a proton pump inhibitor (PPI)
• Insomnia
• Hyperglycemia (particularly relevant in diabetic patients)
• Fluid retention and hypertension

These risks underscore the importance of using corticosteroids judiciously and for the shortest effective duration.

---

Diagnosis

The diagnosis of optic neuritis is fundamentally clinical, based on the characteristic history and findings on ophthalmological and neurological examination. However, a range of investigations is needed to confirm the diagnosis, assess the degree of nerve damage, and, most importantly, identify any underlying systemic condition.

Clinical Examination

Ophthalmological assessment includes:

• Visual acuity testing: Assessment of best-corrected visual acuity in each eye separately. In optic neuritis, acuity in the affected eye is typically reduced. A key clinical observation is that patients may not be fully aware of their color perception deficit until formally tested by covering the healthy eye.

• Fundoscopy (ophthalmoscopy): Direct visualization of the optic disc and posterior pole. In papillitis, the disc appears swollen, hyperemic, and with blurred margins, while in retrobulbar neuritis, it looks entirely normal. This difference is diagnostically important.

• Pupillary light reflex (swinging flashlight test): Assesses the integrity of the afferent visual pathway. An afferent pupillary defect (APD), also called a Marcus Gunn pupil, is identified when the affected eye shows paradoxical dilation instead of constriction when the light is swung from the healthy eye to the affected one. This finding reflects asymmetric optic nerve conduction and is one of the most objective signs in optic neuritis.

• Color vision testing (e.g., Ishihara plates, Farnsworth-Munsell 100-hue test): Documents the degree of dyschromatopsia, which may be disproportionate to the loss of acuity.

• Visual field testing (perimetry): Maps the extent and pattern of visual field loss (scotoma).

Electrophysiological Testing

• Visual Evoked Potentials (VEP): Measures the electrical response of the visual cortex to patterned visual stimuli (usually a reversing checkerboard). In optic neuritis, VEP typically reveals a delayed P100 waveform, which means the latency is prolonged. This indicates slowed conduction through demyelinated nerve fibers. Interestingly, this finding can persist even after the patient has recovered clinically and visual acuity appears normal. This is particularly valuable for detecting subclinical or previous optic neuritis in patients with suspected MS.

Neuroimaging

• Brain and orbital MRI with gadolinium contrast: The single most important investigation. Key findings include:

  • Enhancement (gadolinium uptake) of the affected optic nerve: reflecting active inflammation and blood-nerve barrier breakdown
  • Enlargement of the optic nerve on fat-suppressed sequences
  • White matter lesions in the brain: the presence, number, and distribution of T2/FLAIR hyperintensities strongly predicts the risk of MS conversion (as per the McDonald criteria)
  • In NMOSD: optic nerve involvement may be particularly extensive (involving the chiasm), and spinal cord lesions are typically present

• CT scan: Generally less useful for soft tissue assessment than MRI, but may be used in emergencies or when MRI is contraindicated.

Structural Retinal Imaging

• Optical Coherence Tomography (OCT): A non-invasive, high-resolution imaging technique that measures the thickness of the retinal nerve fiber layer (RNFL). This measurement serves as a direct surrogate for optic nerve axonal integrity. OCT can:
  • Document RNFL thinning in the affected eye following optic neuritis (reflecting axonal loss)
  • Monitor disease progression over time
  • Detect subclinical optic nerve involvement in the fellow eye
  • Support the diagnosis of optic atrophy

Blood Tests and Systemic Workup

Because optic neuritis can be the presenting manifestation of a wide range of systemic diseases, the following laboratory investigations are typically requested:

• Complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
• Antibody testing: Check for anti-AQP4 (aquaporin-4) and anti-MOG antibodies, as these are essential to exclude NMOSD, which is associated with a more severe prognosis
• Antinuclear antibodies (ANA), anti-dsDNA: systemic lupus erythematosus
• ANCA: vasculitis
• ACE (angiotensin-converting enzyme) level: sarcoidosis
• Serological testing for syphilis (TPHA/VDRL), HIV, tuberculosis (QuantiFERON), Lyme disease (Borrelia antibodies), and other infectious agents as clinically indicated
• Vitamin B12 levels: pernicious anemia can rarely cause optic neuropathy
• Thyroid function tests

---

Treatment

The prognosis of optic neuritis depends substantially on the underlying cause and the severity of the initial episode. In the majority of cases (particularly isolated or MS-associated optic neuritis), vision recovers spontaneously over 2 to 3 months, even without specific treatment.

However, a minority of patients may experience incomplete recovery and persistent visual deficits, especially those with NMOSD-associated optic neuritis, bilateral disease, or very severe initial vision loss.

Corticosteroid Therapy

Intravenous (IV) methylprednisolone, typically given at 1 g/day for 3 to 5 days, remains the cornerstone of acute treatment for optic neuritis. Based on the evidence from the Optic Neuritis Treatment Trial (ONTT):

• IV methylprednisolone accelerates visual recovery compared to placebo or oral prednisone.
• It reduces the risk of MS relapse in the short term (over 2 years), particularly in patients with multiple MRI brain lesions.
• However, it does not improve the final visual outcome at 6 months or beyond compared to placebo.
• Oral prednisone alone (at standard doses) should not be used as a substitute for IV therapy in acute optic neuritis. In the ONTT, this approach was associated with an increased relapse rate, a counterintuitive but important finding.

The decision to treat with IV steroids depends on the severity of vision loss, the clinical context (e.g., risk of MS conversion), and patient preference.

Disease-Modifying Therapy (DMT) for Multiple Sclerosis

In patients diagnosed with or at high risk of developing MS following an episode of optic neuritis, long-term disease-modifying therapy is discussed and typically initiated:

• Interferon-beta (IFN-β) preparations (e.g., interferon beta-1a, interferon beta-1b).
• Glatiramer acetate.
• Natalizumab, dimethyl fumarate, fingolimod, cladribine, and ocrelizumab are higher-efficacy agents for more active disease.

These treatments aim to reduce the frequency and severity of MS relapses and slow the accumulation of neurological disability over time.

Immunosuppressive Therapy for NMOSD

In neuromyelitis optica spectrum disorder, aggressive immunosuppression is required to prevent relapses, which tend to be more severe and less reversible than in MS:

• Rituximab (anti-CD20 monoclonal antibody).
• Azathioprine plus oral prednisolone.
• Mycophenolate mofetil.
• Eculizumab, satralizumab, and inebilizumab are recently approved targeted therapies for AQP4-antibody positive NMOSD.

Management of Toxic and Infectious Causes

• Toxic optic neuritis: immediate cessation of the causative agent (for example, ethambutol). The longer exposure continues after vision symptoms appear, the greater the risk of permanent damage.
• Infectious optic neuritis: appropriate antimicrobial therapy for the underlying infection (antibiotics for bacterial causes, antivirals for viral encephalitis, antifungals, anti-tuberculous therapy, etc.)

Supportive Measures and Visual Rehabilitation

During and after recovery, several practical measures can assist patients:

• Magnifying lenses for reading
• Large-print materials and screen magnification software
• Talking clocks, audiobooks, and screen-reader technology
• Low vision rehabilitation services
• Avoiding heat exposure and fever (to minimize Uhthoff’s symptom exacerbation)
• For patients with persistent significant visual impairment: formal visual rehabilitation with a low vision specialist and occupational therapist

---

Sources and Bibliography

• MSD Manual Professional Edition. Optic Neuritis.
• Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurology. 2014;13(1):83–99. DOI: 10.1016/S1474-4422(13)70259-X
• The Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology. 1997;49(5):1404–1413.
• Mayo Clinic. Optic neuritis: Symptoms and causes.
• Petzold A, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology. 2017;16(10):797–812.
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
• Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. New England Journal of Medicine. 1992;326(9):581–588.
• Trobe JD. The Neurology of Vision. Oxford University Press; 2001.